Show simple item record

dc.contributor.authorAlene, Kefyalew
dc.contributor.authorJegnie, A.
dc.contributor.authorAdane, A.A.
dc.date.accessioned2021-11-17T09:46:33Z
dc.date.available2021-11-17T09:46:33Z
dc.date.issued2021
dc.identifier.citationAlene, K.A. and Jegnie, A. and Adane, A.A. 2021. Multidrug-resistant tuberculosis during pregnancy and adverse birth outcomes: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology. 128 (7): pp. 1125-1133.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/86487
dc.identifier.doi10.1111/1471-0528.16573
dc.description.abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) is a major global public health concern. However, there is a dearth of literature on whether MDR-TB and its medications impact maternal and perinatal outcomes, and when such evidence exists the findings are conflicting.

Objectives: This systematic review and meta-analysis aimed to examine the impact of MDR-TB and its medications during pregnancy on maternal and perinatal outcomes. Search strategy: PubMed, Scopus and Web of Science databases were searched from earliest to February 2020.

Selection criteria: Records were screened based on pre-defined selection criteria and assessed for quality by two independent reviewers.

Data collection and analysis: A meta-analysis was performed using the random effects model to calculate pooled prevalence for each outcome.

Main results: Of the 72 records identified, 12 were included in the systematic review and meta-analysis, consisting of 174 pregnant women with MDR-TB and 110 adverse outcomes. Maternal death, pregnancy loss, preterm birth and low birthweight were the most common maternal and perinatal adverse outcomes reported in the studies. The overall pooled prevalence was 7.5% (95% CI 3.2–12.8) for maternal death, 10.6% (95% CI 6.0–16.3) for pregnancy loss, 12.9% (95% CI 0.0–38.0) for preterm birth and 23.7% (95% CI 17.0–31.0) for low birthweight.

Conclusions: The findings suggest that MDR-TB is associated with a high risk of adverse maternal and perinatal outcomes, but these should be interpreted cautiously because the evidence is largely preliminary. Adequately powered prospective cohort studies are urgently required to corroborate these findings. Tweetable abstract: Multidrug-resistant tuberculosis may increase the risk of adverse maternal and perinatal outcomes.

dc.languageEnglish
dc.publisherWILEY
dc.relation.sponsoredbyhttp://purl.org/au-research/grants/nhmrc/1196549
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectObstetrics & Gynecology
dc.subjectAdverse maternal outcomes
dc.subjectadverse perinatal outcomes
dc.subjectmeta&#8208
dc.subjectanalysis
dc.subjectmultidrug&#8208
dc.subjectresistant tuberculosis
dc.subjectresistant tuberculosis medications
dc.subjectsystematic review
dc.subjectGLOBAL BURDEN
dc.subjectHIV COINFECTION
dc.subjectMORTALITY
dc.subjectMANAGEMENT
dc.subjectAFRICA
dc.subjectDEATH
dc.subjectWOMEN
dc.titleMultidrug-resistant tuberculosis during pregnancy and adverse birth outcomes: a systematic review and meta-analysis
dc.typeJournal Article
dcterms.source.volume128
dcterms.source.number7
dcterms.source.startPage1125
dcterms.source.endPage1133
dcterms.source.issn1470-0328
dcterms.source.titleBJOG: An International Journal of Obstetrics and Gynaecology
dc.date.updated2021-11-17T09:46:33Z
curtin.departmentCurtin School of Population Health
curtin.accessStatusFulltext not available
curtin.facultyFaculty of Health Sciences
curtin.contributor.orcidAlene, Kefyalew [0000-0002-1904-4682]
curtin.contributor.researcheridAlene, Kefyalew [V-8240-2018]
dcterms.source.eissn1471-0528
curtin.contributor.scopusauthoridAlene, Kefyalew [57202583764]


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record